Navigation Links
Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical Development
Date:11/15/2010

f SPECT imaging.  As noted in the publication, the mean change observed in Generx-treated patients was a 4.2% absolute reduction (which represents a 20% relative reduction) in the reversible perfusion defect size from baseline at eight weeks (p<0.001), while the placebo group showed only a 1.6% absolute reduction from baseline (not significant) at eight weeks following treatment.  The observed treatment effect for patients receiving Generx was similar in magnitude to that reported in the literature for patients undergoing angioplasty/stent or revascularization procedures with reversible perfusion defects of comparable size at one year following these procedures.

About CardiumCardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium lifestyle medicinals brand platform.  The Company's lead product candidates include: (1) Excellagen™ topical gel, for wound care management, which Cardium plans to market launch in the fourth quarter subject to pending FDA 510(k) clearance; and (2) Generx®, a DNA-based angiogenic cardiovascular biologic for patients in international markets with coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.  News from Cardium is located at www.cardiumthx.com.


'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Aware, Inc. Reports Third Quarter 2010 Financial Results
2. Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean
3. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
4. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
5. GEN reports on the greening of the life sciences
6. Aware, Inc. Reports Second Quarter 2010 Financial Results
7. GEN reports on rediscovered technology to bolster proteomics research
8. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
9. International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit
10. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
11. New climate change reports underscore need for action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 7, 2014 According to ... "Electronic Access Control Systems Market Global Forecast, Market Share, ... global Electronic Access Control systems market was valued at ... grow at a CAGR of 12.6% from 2014 to ... million in 2019. Browse the full Electronic ...
(Date:7/10/2014)... NORTHFIELD, Ill. , July 9, 2014 /PRNewswire-USNewswire/ ... record (EHR), spurred in large part by meaningful ... way health care providers interact with laboratory information. ... well-versed in the field of clinical informatics in ... care. To address the educational needs ...
(Date:7/10/2014)... German . An ... a central step of photosynthesis in action for the first ... State University used the world,s most powerful X-ray flashlight at ... of a molecular complex called photosystem II as it splits ... oxygen in earth,s atmosphere. The researchers report their results in ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4Scientists watch photosynthesis in action 2Scientists watch photosynthesis in action 3
... a common feature in IBS and in fact may be ... on a lactulose breath test may indicate SIBO. Antibiotics and ... SIBO, but the efficacy of probiotics is untested. A pilot ... Shirota (Yakult(R)) on intestinal fermentation patterns of IBS patients. After ...
... interoperability during ePassports EAC ... Interoperability Tests in Prague, DALLAS, Sept. 9 ... Slovenia again has,selected Entrust, Inc. (Nasdaq: ENTU ) ... based on the Extended,Access Control (EAC) standard. With this, ...
... its intellectual and innovative strengths the betterment of the ... the betterment of us all. According to its ... Property and Commercialization shows that the institution continues to ... productivity and delivering new ideas to the marketplace. ...
Cached Biology News:Is yakult helpful in the treatment of irritable bowel syndrome? 2Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 2Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 3Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 4Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 5A reputation for innovation 2
(Date:7/11/2014)... 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) ... (eslicarbazepine acetate) for use as a once-daily adjunctive therapy ... epilepsy who are not satisfactorily controlled with conventional therapy. ... patients under 18 years of age. ... and according to Epilepsy Canada, it affects 0.6% of ...
(Date:7/10/2014)... Deep Knowledge Ventures last week sponsored ... Longevity Research’ and welcomed a host of London-based ... Innovation Center for the event, organised by the ... The meeting highlighted the need for both philanthropic ... disease, as well as the crucial role of ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... , , BOTHELL, ... BLFS), a leading manufacturer and marketer of biopreservation tools for ... into a non-exclusive distribution agreement with STEMCELL Technologies, Inc., based ... StemCell Group of companies, is a leading provider of products ...
... international ports could be the most affordable approach to ... not carrying nuclear bombs, according to a paper being ... the Institute for Operations Research and the Management Sciences ... in place that relies on targeting only a small ...
... and Washington DC (July 27, 2009) According to a ... Making , a large-scale, covert anthrax attack on a ... extremely effective public health response, primarily because of expected ... to it. The article "Predicting Hospital Surge after ...
Cached Biology Technology:BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 4Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2
HybriWell™ hybridization sealing system, 22 mm x 22 mm chamber, 0.15 mm deep *set of 100*...
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
Recombinant Equine IL-4, CF...
Biology Products: